Back to News

Aragen Life Sciences to begin Operations at OneHP, an Integrated High-potency Platform in Hyderabad

• OneHP brings together discovery, process development and cGMP manufacturing for highly potent molecules, reducing handoffs across the development journey
• ~15,000 sq ft OEB-6 platform designed for up to 600 kg of API a year

Hyderabad, India, 6th October 2026: Aragen Life Sciences, among the top three largest Indian CRDMOs, has begun operations at Aragen OneHP, a high-potency development and manufacturing platform at its Nacharam campus in Hyderabad. The platform adds capabilities for highly potent molecules, including cytotoxic payloads used in oncology, while providing customers with an integrated pathway from milligram-scale discovery through process development and multi-kilogram cGMP manufacturing.

Aragen OneHP spans approximately 15,000 sq ft and operates one manufacturing line with a designed capacity of 500 to 600 kg of active pharmaceutical ingredient a year. The platform can support highly potent compounds, including cytotoxic molecules and targeted Oncology therapies, and will lay the foundation for future expansion into advanced modalities. OneHP will offer an integrated pathway from development through clinical and commercial supply worldwide, with manufacturing spanning small-scale chemistry synthesis (up to 10 g), non-GMP process development and scale-up (up to 500 g), and cGMP manufacturing (500 g to 5 kg per batch). Advanced containment systems are designed to handle compounds at occupational exposure limits of up to 10 ng/m³, subject to ongoing validation.

The platform is the most recent addition to Aragen’s continuous expansion programme adding new capabilities. Aragen spent more than ₹1000 crores on capital expenditure over last three years to March 2026, building capability across small molecules and biologics. Its contract development and manufacturing business grew at a 19% compound annual rate over that period alongside a contract research arm that grew at 12%. Installed small-molecule capacity stood at 364 KL across Hyderabad and Visakhapatnam as of March 31, 2026. The company drew nearly 95% of revenue from global customers in the year ending March 2026, and served 591 customers globally in that year, including 16 of the world’s Top 20 Big pharmaceutical companies.

Mr. Aniel Khubchandani, Chief Executive Officer – Small Molecules-CDMO, Aragen Life Sciences, said, “With OneHP, we are bringing discovery, development and cGMP manufacturing for highly potent molecules onto a more integrated platform. This can reduce handoffs between providers, while keeping process knowledge and programme context connected as a molecule moves from early development towards commercial supply.”

Highly potent molecules, including cytotoxic compounds, require specialised handling, containment and manufacturing infrastructure. OneHP will bring together capabilities across small-scale chemistry synthesis, process development, scale-up and cGMP manufacturing, enabling customers to progress programmes through an integrated platform. The platform also lays the foundation for Aragen’s future expansion into advanced modalities such as antibody-drug conjugates and peptide-drug conjugates. Aragen’s Hyderabad manufacturing and analytical operations are accredited by the USFDA, EDQM, PMDA, MFDS, ANVISA, WHO Geneva and CDSCO.

About Aragen Life Sciences

Aragen Life Sciences is a fully integrated contract research, development and manufacturing organization (CRDMO), serving global innovator companies and emerging firms in the life sciences industry.  The company offers comprehensive solutions across the entire drug development lifecycle spanning contract discovery and pre-clinical research solutions and contract development and manufacturing solutions for both small molecules and biologics.  It partners with innovators, pharmaceutical, biotechnology, animal health and agrochemical companies to accelerate journey from molecules to medicines. Through integrated capabilities across Discovery, Development and Manufacturing, Aragen enables the customer to advance programs efficiently from early research through commercialization.

The company operates a global network of R&D and manufacturing facilities across Hyderabad, Bengaluru, Visakhapatnam and Pune in India, and Morgan Hill, California in the United States, supported by a team of 4,362 employees as of March 31, 2026. Aragen is recognized among India’s Top 100 Best Companies to work for by Great Place to Work® and is the only Indian CRDMO to earn Great Place To Work certification for seven consecutive years., It holds a Gold EcoVadis sustainability rating, placing the company among the top 5% globally. Through scientific expertise, a customer-focused approach, flexible engagement models and robust project management, Aragen serves leading global life sciences organizations in advancing innovation and improving outcomes.

Visit www.aragen.com for more details.

Media Contacts:

Prasad Babu, prasad.babu@aragen.com +91 91546 68768